Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Similar articles for PubMed (Select 24298433)

1.

Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.

Edavana VK, Penney RB, Yao-Borengasser A, Williams S, Rogers L, Dhakal IB, Kadlubar S.

Springerplus. 2013 Nov 20;2:620. doi: 10.1186/2193-1801-2-620. eCollection 2013.

2.

Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy.

Chen H, Yang K, Choi S, Fischer JH, Jeong H.

Drug Metab Dispos. 2009 Sep;37(9):1841-7. doi: 10.1124/dmd.109.026609. Epub 2009 Jun 22.

3.

Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Edavana VK, Dhakal IB, Williams S, Penney R, Boysen G, Yao-Borengasser A, Kadlubar S.

Drug Metab Dispos. 2013 Apr;41(4):870-7. doi: 10.1124/dmd.112.048157. Epub 2013 Jan 31.

4.

Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.

Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K.

Breast Cancer Res Treat. 2012 May;133(1):145-59. doi: 10.1007/s10549-011-1731-8. Epub 2011 Aug 24.

PMID:
21863258
5.

Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.

Long X, Fan M, Nephew KP.

Cancer Biol Ther. 2010 Mar 1;9(5):389-96. Epub 2010 Mar 11.

7.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
8.

Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.

Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP.

Cancer Res. 2006 Dec 15;66(24):11954-66.

9.

Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.

Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T.

PLoS One. 2013 Apr 4;8(4):e60889. doi: 10.1371/journal.pone.0060889. Print 2013.

10.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.

Endocr Relat Cancer. 2006 Dec;13(4):1121-33.

11.
12.

Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.

Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC.

Int J Oncol. 2006 Nov;29(5):1237-46.

PMID:
17016657
13.

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD.

Mol Med. 2012 Sep 7;18:913-29. doi: 10.2119/molmed.2012.00010. Erratum in: Mol Med. 2012;18: doi/10.2119/molmed.2012.00006.erratum.

14.

Induction of UDP-Glucuronosyltransferase 2B15 Gene Expression by the Major Active Metabolites of Tamoxifen, 4-Hydroxytamoxifen and Endoxifen, in Breast Cancer Cells.

Chanawong A, Hu DG, Meech R, Mackenzie PI, McKinnon RA.

Drug Metab Dispos. 2015 Jun;43(6):889-97. doi: 10.1124/dmd.114.062935. Epub 2015 Mar 20.

PMID:
25795461
15.

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.

Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P.

Breast Cancer Res. 2006;8(4):R50.

16.

Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.

Sui M, Jiang D, Hinsch C, Fan W.

Breast Cancer Res Treat. 2010 Jun;121(2):335-45. doi: 10.1007/s10549-009-0472-4. Epub 2009 Jul 22.

PMID:
19626437
17.

Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein.

Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T.

Cancer Res. 2006 Oct 15;66(20):10153-61.

18.

Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.

Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.

Mol Cancer Res. 2008 Aug;6(8):1347-55. doi: 10.1158/1541-7786.MCR-07-2179.

19.

Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer.

Zhao H, Lo YH, Yu L, Wang SC.

Mol Carcinog. 2011 May;50(5):383-9. doi: 10.1002/mc.20721. Epub 2010 Dec 28.

PMID:
21480391
20.

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.

Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y.

Breast Cancer Res. 2001;3(4):253-63. Epub 2001 Apr 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk